Who makes fospropofol disodium Subgroup 3 Approved Dose?

fospropofol disodium Subgroup 3 Approved Dose is developed by Eisai Inc..

What development phase is fospropofol disodium Subgroup 3 Approved Dose in?

fospropofol disodium Subgroup 3 Approved Dose is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

fospropofol disodium Subgroup 3 Approved Dose

Eisai Inc. · FDA-approved active Small molecule Quality 2/100

Fospropofol disodium, marketed by Eisai Inc., is an approved drug in Subgroup 3 with a key composition patent expiring in 2028. The's. Its primary market position is currently undefined due to the lack of revenue data. However, it remains a significant component of Eisai's portfolio. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	fospropofol disodium Subgroup 3 Approved Dose
Sponsor	Eisai Inc.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

fospropofol disodium Subgroup 3 Approved Dose CI brief — competitive landscape report
fospropofol disodium Subgroup 3 Approved Dose updates RSS · CI watch RSS
Eisai Inc. portfolio CI